Meningococcemia (Meningococcal Infections) - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 42

Meningococcemia (Meningococcal Infections) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Meningococcemia (Meningococcal Infections) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections). Meningococcemia (Meningococcal Infections) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Meningococcemia (Meningococcal Infections).
- A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Meningococcemia (Meningococcal Infections).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Meningococcemia (Meningococcal Infections) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Meningococcemia (Meningococcal Infections) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Meningococcemia (Meningococcal Infections) 7
Meningococcemia (Meningococcal Infections) Therapeutics under Development by Companies 9
Meningococcemia (Meningococcal Infections) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Meningococcemia (Meningococcal Infections) Therapeutics – Products under Development by Companies 13
Meningococcemia (Meningococcal Infections) Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Meningococcemia (Meningococcal Infections) Therapeutics Development 15
GlaxoSmithKline plc 15
Pfizer Inc. 16
Serum Institute of India Limited 17
Meningococcemia (Meningococcal Infections) – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Meninge ACYW conjugate - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PsA TT - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GSK-134612 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Menitorix + Priorix - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Conjugated Meningococcal C Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Group A, C Polysaccharide Meningococcal + Type b Haemophilus Influenzal Conjugate Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rLP-2086 + Gardasil - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Meningococcemia (Meningococcal Infections) Therapeutics – Drug Profile Updates 38
Meningococcemia (Meningococcal Infections) Therapeutics - Dormant Products 39
Meningococcemia (Meningococcal Infections) – Product Development Milestones 40
Featured News & Press Releases 40
Dec 23, 2010: Novartis Submits Meningococcal B Vaccine For Regulatory Review In Europe 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Meningococcemia (Meningococcal Infections), H2 2012 7
Products under Development for Meningococcemia (Meningococcal Infections) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
GlaxoSmithKline plc, H2 2012 15
Pfizer Inc., H2 2012 16
Serum Institute of India Limited, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Meningococcemia (Meningococcal Infections) Therapeutics – Drug Profile Updates 38
Meningococcemia (Meningococcal Infections) Therapeutics – Dormant Products 39

List of Figures
Number of Products under Development for Meningococcemia (Meningococcal Infections), H2 2012 7
Products under Development for Meningococcemia (Meningococcal Infections) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Customers who bought this item also bought

• Meningitis - Pipeline Review, H2 2012
• Fungal Infections - Pipeline Review, H2 2012
• Other Viral Infections - Pipeline Review, H2 2012
• Urinary Tract Infections - Pipeline Review, H2 2012
• Influenza A Infections - Pipeline Review, H2 2012
• Rotavirus Infections - Pipeline Review, H2 2012
• Bacterial Respiratory Tract Infections - Pipeline Review, H2 2012
• Other Bacterial Infections - Pipeline Review, H2 2012
• Infections Caused By Picornaviridae - Pipeline Review, H2 2012
• Clostridium Botulinum Infections - Pipeline Review, H2 2012